The potential for alirocumab to reduce cardiovascular events will be investigated in the large, phase III ODYSSEY Outcomes study. This trial is currently recruiting and aims to accrue around 18,000 high-risk patients including those with diabetes. The study is projected to complete by the end of 2017.
News
Lipid-lowering Benefits of Alirocumab Extend to Patients With High-risk Diabetes
Publish date: October 1, 2015
Author and Disclosure Information
Sara Freeman, Family Practice News Digital Network
AT EASD 2015